Trial reportPaediatric drugs2018
Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial.
Trial report in Paediatric drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01487993. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents
Open the trial in the graphWho cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Safety and tolerability of metformin in overweight and obese patients with dengue: An open-label clinical trial (MeDO).PLoS neglected tropical diseases · 2025Trial
- A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents.European journal of clinical pharmacology · 2019 · on this mapTrial
- Dosing Strategies for High-Alert Medications in Obese Pediatric Patients: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Reduced Metformin Concentrations in Obese Women With Human Immunodeficiency Virus Treated With Dolutegravir.The Journal of infectious diseases · 2025Observational
- Low metformin concentrations in obese people with HIV treated with dolutegravir.African journal of primary health care & family medicine · 2025Article
- The Impact of Drug Properties and Severity of Obesity on Renal Drug Clearance Through Glomerular Filtration and Active Tubular Secretion: A Systematic Analysis Using PBPK Modeling.Pharmaceutical research · 2025Article
- Factors contributing to variability in metformin concentration in polycystic ovary syndrome.Croatian medical journal · 2024Article
- The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine.Pharmaceutics · 2024Article
- Body water percentage from childhood to old age.Kidney research and clinical practice · 2023Article
- Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents.Clinical pharmacokinetics · 2023Article
- Drug dosing in children with obesity: a narrative updated review.Italian journal of pediatrics · 2022Review
- Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents With Obesity.Journal of clinical pharmacology · 2022Article
- Development and application of a pediatric mechanistic kidney model.CPT: pharmacometrics & systems pharmacology · 2022Article
- Research Progress of Population Pharmacokinetic of Metformin.BioMed research international · 2022Review
- Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years.The AAPS journal · 2021Article
- Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities.Paediatric drugs · 2020Review
- Metformin as adjunctive therapy for dengue in overweight and obese patients: a protocol for an open-label clinical trial (MeDO).Wellcome open research · 2020Article
- Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.Gastroenterology · 2019Article
- Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children.Paediatric drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn view of the increased use of metformin in obese adolescents, the aim of this study was to determine the pharmacokinetics of metformin in overweight and obese adolescents.
methodsIn overweight and obese adolescents receiving metformin 500 or 1000 mg twice daily for 37 weeks during a clinical trial, blood samples were collected over 8 h during an oral glucose tolerance test. Population pharmacokinetic modeling was performed using NONMEM.
resultsData for 22 overweight and obese adolescents with a mean total body weight (TBW) of 79.3 kg (range 54.7-104.9), body mass index (BMI) of 29.1 kg/m
conclusionThe CL/F of metformin in obese adolescents (1.17 l/min) is larger than that in non-obese children (0.55 l/min) and similar to that in adults (1.3 l/min) as reported in the literature. This increase may potentially be explained by increased tubular secretion of metformin. These results appear to indicate that adult dosages of metformin could be considered in obese adolescents if pediatric dosages have been therapeutically ineffective. CLINICALTRIALS.GOV: NCT01487993.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.